FDA advisers consider easing peptide rules

FDA advisers voted in favor of allowing pharmacies to compound the first four of seven unapproved peptides, citing their perceived health benefits, despite safety concerns. The decision was made during a two-day committee meeting, with some members supporting broader access and others emphasizing the need for clinical evidence. The FDA previously banned certain peptides in 2023 due to potential safety risks, but the committee's votes suggest a shift towards increased availability amid ongoing debate.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article